| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
Biostatistics Branch [T. R. F., M. H. G.], Epidemiology and Biostatistics Program [R. G. Z., R. N. H.], Radiation Epidemiology Branch [J. L. D.], Environmental Epidemiology Branch [R. T. F.] and Division of Cancer Epidemiology and Genetics, [J. B. V.], National Cancer Institute, Bethesda, Maryland 20892, and University of Southern California, Keck School of Medicine, Los Angeles, California 90033 [F. Z. S.]
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Laboratory 1.
For ADIOL G, unconjugated steroids were removed by organic extraction, followed by incubation with ß-glucuronidase, enzyme hydrolysis, and celite chromatography and, finally, measurement of ADIOL by RIA. ADION, DHEA, TESTO, and DHT were measured by extracting plasma with ethyl acetate (20%) in hexane, celite column chromatography, and RIA. DHEA S was measured by RIA.
Laboratory 2.
For ADIOL G, plasma was extracted with a polar solvent that was then subjected to complete enzymatic hydrolysis, followed by extraction with hexane:ethyl acetate, purification by high performance liquid chromatography, and measurement by RIA. ADION, DHEA, and TESTO were measured after extraction with hexane:ethyl acetate, followed by RIA. For DHEA S, the sulfate was removed by overnight hydrolysis with sulfatase, after which the procedures for measuring DHEA were followed. For DHT, extraction with hexane:ethyl acetate was followed by treatment with a strong oxidizer to destroy unsaturated steroids and purification on alumina columns.
Laboratory 3.
DHEA S was quanitified by direct RIA after a 1000-fold dilution of the plasma sample with assay buffer. DHEA, ADION, TESTO, DHT, and ADIOL were measured by RIA after extraction of plasma with diethyl ether and purification by celite column chromatography. ADIOL G was quantified directly in plasma using a commercial kit. ANDRO S and ANDRO G were measured after unconjugated steroids were removed by extraction with diethyl ether. The conjugated steroids were hydrolyzed utilizing hydrochloric acid or glucuronidase followed by extraction with ethyl acetate and purification by celite column chromatography.
Laboratory 4.
ADION was measured by carbon tetra-chloride extraction of plasma followed by a RIA kit. DHEA was measured by dichloromethane extraction and a RIA. DHEA S and TESTO were assayed directly using RIA. Further details of the assay procedures are provided in Fears et al. (2)
.
A blood sample was obtained from each of five male volunteers from NCI, ages 31, 45, 47, 50, and 67 years. Each volunteer was in good health, with no known hormonal abnormality. Within 24 h of draw, the plasma was separated, aliquoted, and stored at -70°C (see Ref. 1 ). Each participating laboratory received four batches of samples, with one batch to be assayed on each of four consecutive months. Each batch contained two aliquots from each of the five subjects. Each aliquot was assayed in duplicate. The order of the 10 aliquots within each batch was randomly assigned.
A nested components of variance analysis was performed using logarithmically transformed measurements to stabilize variances (1) . Components were estimated for subjects, days, aliquots, and replicates. We used three measures of reproducibility derived from these components. The CV, which is the SD divided by the mean, is the usual measure of reproducibility. The sum of the components associated with day, aliquot, and replicate is a good estimate of the square of the CV. The ICC is the correlation between measurements on different days from a given sample. It is the ratio of the component associated with subjects to the sum of all components. The MDRD is the minimum difference that is reliably detected with a given number of cases and controls. The CV is of primary interest to the laboratory for quality control, whereas the ICC and MDRD are more important to the epidemiologist in determining the feasibility of an epidemiological study.
As in the earlier studies, for each hormone and laboratory, we examined graphs of grand means, daily means and aliquot means (available on request). The Friedman rank order statistic was used to compare subject means across laboratories, and Spearman rank correlations were used to measure concordance of the participants grand means across laboratories. The estimated components of variance are given in the "Appendix ." The components of variance
were used to obtain estimates of the CVs, ICCs, and MDRDs that were compared among the laboratories. To calculate ICCs and CVs, we assumed that the measurement used was the mean of the two logarithmic-transformed replicates. To calculate MDRDs, we assumed n1 = 300 cases and n2 = 600 controls, as in our earlier reports. Further details of these statistical methods are presented in Fears et al. (2)
. The estimates and their 95% CIs are given in Table 1
.
|
|
| Results |
|---|
|
|
|---|
ADION.
The mean levels of Ln(ADION) differed across laboratories (P = 0.002). Grand means were 4.19, 4.46, 4.07, and 4.27 at laboratories 1, 2, 3, and 4, respectively. The ranks of the subjects mean responses were, however, highly correlated (0.901.00). The CVs for ADION were 20% or less at all four laboratories (9% and 11% at laboratories 3 and 4 and 18% and 20% at laboratories 1 and 2). The ICCs were 92% and 94% at laboratories 3 and 4 and 80% and 66% at laboratories 1 and 2. The MDRDs ranged from 10% to 13%.
DHEA.
The mean levels of Ln(DHEA) from these laboratories differed across laboratories (P = 0.002). Grand means were 5.25, 5.48, 5.63, and 4.69 at laboratories 1, 2, 3, and 4, respectively. The ranks of the subjects mean responses were, however, perfectly correlated. The ICC was above 93% at all the laboratories. The CV was 17% at laboratory 4 and less than 13% at the other laboratories. The MDRDs were between 15% and 17% at laboratories 2 and 3 but above 20% at laboratories 1 and 4.
DHEA S.
The mean levels of Ln(DHEA S) differed by laboratory (P = 0.004). Grand means were highest at laboratories 1 and 3 (5.08 and 5.14) and were quite different from the mean levels at laboratories 2 and 4 (4.62 and 4.97, respectively). The ranks of the subjects means were perfectly correlated. The ICC was 98% or higher at all laboratories. The CV at laboratory 1 was 10%, and other laboratories had CVs of 8% or less. The MDRD ranged from 20% to 25%.
DHI.
There was weak evidence (P = 0.07) that the subject mean levels of Ln(DHT) differed by laboratory. The grand mean was lowest at laboratory 1 (3.68) versus 3.77 and 3.76 at laboratories 2 and 3, respectively. The ranks of the subjects means were highly correlated (0.901.00). The ICC was only 76% at laboratory 3 and 9295% at laboratories 1 and 2. Similarly, the CV was 16% at laboratory 3 and 810% at laboratories 1 and 2. The MDRD ranged from 10% to 11%.
TESTO.
The mean levels of Ln(TESTO) were comparable (P = 0.36). The grand means were 5.99, 6.02, 6.01, and 5.91 at laboratories 1, 2, 3 and 4, respectively. The correlations of the ranks of the subjects mean responses ranged from 0.70 to 1.00. The ICC was 85% and 89% at laboratories 1 and 2, respectively, and less at laboratories 3 and 4 (71% and 57%, respectively). The CVs were less than 13% at laboratories 1 and 2 but were 21% and 35% at laboratories 3 and 4, respectively. The MDRDs were 1012% at laboratories 1, 2, and 3 and 17% at laboratory 4.
ADIOL, ANDRO G, and ANDRO S.
Only laboratory 3 conducted these assays. For ADIOL, the ICC was not large (63%), the CV was relatively high (22%), and, because the total variation was small, the MDRD was small (11.4%). The ICC for ANDRO G was 84%, the CV was 21%, and the MDRD was 17%. For ANDRO S, the ICC was low (59%), and the CV was high (36%); however, the MDRD was only 18%.
| Discussion |
|---|
|
|
|---|
Laboratory 3 was the only laboratory that volunteered to assay ANDRO G, ANDRO S, and ADIOL. The ICCs were relatively low (84% for ANDRO G but less than 65% for ANDRO S and ADIOL). The CVs were fairly high, ranging from 21% to 36%. Nevertheless, the MDRDs were low, ranging from 12% to 18%.
A larger number of men would be desirable to estimate the components of variance, especially the subject component, with greater precision
. However, even five men are sufficient to yield usefully precise estimates in many instances, as indicated by the confidence intervals in Table 1
. For example, for DHEA in laboratory 4, the estimated ICC was 95.9% with a 95% CI of 90.1100.0%. The CIs are larger for assays with lower ICC point estimates, e.g., ADIOL, ICC = 63.4% and CI, 27.599.3%. The results in Table 1
indicate that the ICC significantly exceeds 0.80 for at least one laboratory with ADIOL G, ADION, DHEA, DHEA S, and DHT, indicating that a single sample with two laboratory replicates/sample yields sufficiently high ICC values for field studies. In contrast ANDRO G, TESTO, ADIOL, and ANDRO S do not meet this test.
A separate issue from precision is whether samples from the NCI volunteers can form a basis for generalization to the population of participants in an etiologic field study. An ideal experiment would recruit a random sample from potential participants in a field study. Questions of generalization could arise even in that context, however, because data would be available only on those who agreed to provide blood samples for a reliability study. We are unaware of any evidence that volunteers for the NCI study are unrepresentative of the general population with respect to parameters such as ICC or MDRD, but this possibility cannot be dismissed.
Fears et al. (2) studied these same assays in women. Assay levels tended to be over 5-fold greater in men than in women. This may account for the smaller CVs for ADIOL G, DHEA, and DHEA S in men. Men have higher ICCs for ADIOL than women, and although the assay is not recommended for women, it might be used with caution in men. For ANDRO G, the ICC was lower for men than for women. Previous recommendations that ADIOL G, DHEA, and DHEA S are suitable for field studies in women also apply to men. In addition, both ADION and DHT may be appropriate for field studies in men but not for women in the midluteal menstrual phase. The previous conclusions that TESTO and ANDRO S can only be used with caution in women also hold for men.
| Appendix 1 |
|---|
|
|
|---|
| Footnotes |
|---|
1 To whom requests for reprints should be addressed at, Biostatistics Branch, National Cancer Institute, 6120 Executive Boulevard, EPS/8040, Bethesda, MD 20892. ![]()
2 The abbreviations used are: NCI, National Cancer Institute; ADIOL G, androstanediol glucuronide; ADION, androstenedione; DHEA, dehydroepiandrosterone; DHEA S, DHEA sulfate; DHT, dihydrotestosterone; TESTO, testosterone; ADIOL, androstanediol; ANDRO G, androsterone glucuronide; ANDRO S, androsterone sulfate; CV, coefficient of variation; ICC, intraclass correlation coefficient; MDRD, minimum detectable relative difference; CI, confidence interval; SD, standard deviation. ![]()
Received 2/ 6/01; revised 4/22/02; accepted 4/25/02.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |